Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2014


Academic Discovery Workshop

23 Sep 2014 - 25 Sep 2014 - Baltimore, MD, USA



Bookmark and Share


The drug discovery landscape is facing many challenges and changes fueled in part with the ongoing de-risking efforts by the Pharma industry; seemingly downsizing their footprint or exiting the space all together. The emerging new paradigm seems to be revolving around academic and non-for-profit institutions to carry out the discovery part of the process across a multitude of therapeutic areas. What has started as a successful interactive workshop for academic screening for the past three years, has now evolved to encompass all discovery aspects from technology development, hit identification, to licensing deals.

This new format will continue to provide delegates the opportunity to learn as well as share experiences about enabling technologies, hit to lead generation, dealing with academic tech transfer offices, identifying and working with CROs, and interrogating the value proposition of functional genomics in translational research. Organised by Dr Hakim Djaballah, Director of the HTS Core Facility at Memorial Sloan Kettering Cancer Center, our 4th Annual Academic Discovery Workshop will take place at the Sheraton Baltimore North in Baltimore from September 23rd-25th. Whether delegates are looking to expand their knowledge, engage in discussions with thought leaders during the afternoon panel discussion sessions, or simply requiring more of an insight to aid and foster future collaborations, this workshop together with the newly established short courses is highly recommended to anyone working or has an interest in drug discovery from academia, research institutes, biotech, and Pharma companies.

The workshop also aims to help energize the discovery paradigm through open panel discussions on highly provocative topics such as “Target-based versus phenotypic-based drug discovery”, “Functional genomics technologies and their impact of target identification”, or "private-public partnerships". it is hoped that through these kind of open discussions, delegates will have the opportunity to build their own consensus and bring their points of view across. We are always seeking new ideas and inputs to help discover novel or repurpose known drugs to fight disease whether in a pharmaceutical or academic setting.

Agenda Topics:

  • Academic Technology Transfer: Due Diligence, Development and Commercialisation
  • Building and Financing Drug Discovery Efforts in Academia
  • Functional Genomics Technologies in 2014
  • Identifying and Working with CRO's
  • Novel and Enabling Screening Technologies in 2014
  • Public - Private Partnerships
  • RNAi and Genome Editing Technologies
  • Target versus Phenotypic Based Discovery
  • Vendor/User Perspectives on HCA in 2014




Further information
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!